MedTrace Logo

Treatment of Children With Insufficient Secretion of Growth Hormone

NCT00271518 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2010-03-17

No results posted yet for this study

Summary

The purpose of this study is to compare a new weekly administered growth hormone preparation with standard daily treatment in children with insufficient secretion of growth hormone

Conditions

  • Growth Hormone Deficiency (GHD)

Interventions

DRUG

growth hormone (somatropin)

dosing regimen is weight based.

Sponsors & Collaborators

  • BioPartners GmbH

    collaborator INDUSTRY

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00271518 on ClinicalTrials.gov